IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.527
NA - Nord America 3.411
AS - Asia 2.624
SA - Sud America 736
AF - Africa 60
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.312
IE - Irlanda 1.244
SG - Singapore 1.221
RU - Federazione Russa 643
BR - Brasile 602
IT - Italia 503
HK - Hong Kong 419
SE - Svezia 393
CN - Cina 366
VN - Vietnam 287
FR - Francia 239
DE - Germania 163
FI - Finlandia 104
GB - Regno Unito 74
BD - Bangladesh 66
AR - Argentina 52
CA - Canada 48
IN - India 43
IR - Iran 43
EC - Ecuador 32
ES - Italia 32
IQ - Iraq 29
NL - Olanda 29
PL - Polonia 28
TR - Turchia 28
MX - Messico 27
ID - Indonesia 21
ZA - Sudafrica 16
JP - Giappone 15
AT - Austria 14
PK - Pakistan 13
AU - Australia 12
CO - Colombia 11
EG - Egitto 11
PY - Paraguay 11
SA - Arabia Saudita 10
VE - Venezuela 10
MA - Marocco 9
BE - Belgio 8
CR - Costa Rica 8
UZ - Uzbekistan 8
CL - Cile 7
UA - Ucraina 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
KZ - Kazakistan 6
OM - Oman 6
DO - Repubblica Dominicana 5
NP - Nepal 5
RO - Romania 5
UY - Uruguay 5
DZ - Algeria 4
GR - Grecia 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
PE - Perù 4
PH - Filippine 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
HU - Ungheria 3
LB - Libano 3
LT - Lituania 3
PS - Palestinian Territory 3
PT - Portogallo 3
TN - Tunisia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DK - Danimarca 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KW - Kuwait 2
MD - Moldavia 2
MK - Macedonia 2
PA - Panama 2
QA - Qatar 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BG - Bulgaria 1
BW - Botswana 1
ET - Etiopia 1
GE - Georgia 1
KG - Kirghizistan 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MY - Malesia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
RS - Serbia 1
Totale 10.370
Salva come PNG Salva come JPEG
Città #
Dublin 1.242
San Jose 897
Chandler 491
Singapore 433
Hong Kong 409
Nyköping 327
Ashburn 320
Santa Clara 176
Beijing 173
Lauterbourg 148
Princeton 134
Ho Chi Minh City 106
Wilmington 84
Helsinki 82
São Paulo 58
Munich 55
Frankfurt am Main 48
Hanoi 42
Dallas 40
Rome 39
Los Angeles 38
New York 36
Des Moines 32
Milan 32
Moscow 26
Shiraz 26
Naples 24
Hillsboro 23
Warsaw 23
Bari 22
Turku 22
Ann Arbor 21
Nuremberg 21
Rio de Janeiro 21
Orem 20
Seattle 20
Serra de' Conti 20
London 19
Council Bluffs 16
Brooklyn 15
Curitiba 15
Paris 15
Montreal 14
Tokyo 14
Assago 13
Granada 13
Thái Bình 13
Brasília 12
Foggia 12
Guangzhou 12
Bexley 11
Chicago 11
Denver 11
Falkenstein 11
Palermo 11
Belo Horizonte 10
Biên Hòa 10
Düsseldorf 10
Quito 10
San Francisco 10
The Dalles 10
Cedar Knolls 9
Karachi 9
Ninh Bình 9
Washington 9
Baghdad 8
Campinas 8
Can Tho 8
Da Nang 8
Kocaeli 8
Madrid 8
Porto Alegre 8
San José 8
Shanghai 8
Stockholm 8
Toronto 8
Atlanta 7
Boston 7
Buenos Aires 7
Guayaquil 7
Jiaxing 7
Mexico City 7
Riyadh 7
St Louis 7
Tehran 7
Vienna 7
Amsterdam 6
Buffalo 6
Cairo 6
Chennai 6
Fortaleza 6
Guarulhos 6
Hải Dương 6
Johannesburg 6
Juiz de Fora 6
Melbourne 6
Pune 6
Santo André 6
Tashkent 6
Alessandria 5
Totale 6.306
Salva come PNG Salva come JPEG
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 235
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 115
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 111
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 111
Approccio clinico e possibilità di trattamento nella SLA 109
CCSVI and MS. A population-based case-control study in Catania, Sicily 107
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 104
An update on the pharmacological management of pain in patients with multiple sclerosis 103
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 98
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 97
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 97
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 96
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 96
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 95
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 94
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 94
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 92
Association between dietary intake and function in amyotrophic lateral sclerosis 92
Can new chemical therapies improve the management of multiple sclerosis in children? 91
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 91
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 90
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 90
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 88
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 88
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 88
Dysphagia in Multiple Sclerosis 87
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 87
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 87
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 87
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 86
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 86
Review: Patient-reported outcomes in multiple sclerosis care 86
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 85
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 85
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 84
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 83
An update on the safety of treating relapsing-remitting multiple sclerosis 82
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 82
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 81
Employment status in MS patients: a population-based study 81
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 80
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 80
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 80
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 80
The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS 79
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 79
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 79
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 78
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 78
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study 77
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 77
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 77
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 76
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 76
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 75
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 75
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 75
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 74
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 74
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 73
Management of dysphagia in multiple sclerosis: current best practice 73
Multiple sclerosis patients preferences in decision making process 72
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 72
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 72
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 71
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 70
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 70
Prevalence of pain in multiple sclerosis: a multicenter italian study 70
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 69
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 69
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 69
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 68
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 68
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 67
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 66
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 66
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 66
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 66
Myeloid-derived Suppressor Cells and Multiple Sclerosis 65
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 65
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 65
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 65
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 65
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 65
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 65
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 65
Five insights from the Global Burden of Disease Study 2019 64
Palliative care in progressive multiple sclerosis 64
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 64
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 64
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 64
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 64
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 63
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 63
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 62
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 62
Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults 61
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 61
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 60
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 60
Totale 8.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/2022893 5 0 1 0 363 30 14 47 97 93 21 222
2022/20232.663 270 115 199 121 48 210 16 182 1.373 45 52 32
2023/2024480 57 47 31 32 75 58 30 52 26 19 19 34
2024/20252.309 110 72 68 42 41 265 341 107 586 150 230 297
2025/20264.751 213 529 582 887 186 134 716 448 471 287 135 163
Totale 11.121